New consensus treatment plans state that the combination of glucocorticoids and immunosuppression is treatment of choice for newly diagnosed pediatric patients with proliferative lupus nephritis. However, variations exist in the steroid protocol and in the type of immunosuppressant used, indicating that a gold-standard treatment protocol is yet to be achieved.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mina, R. et al. Consensus treatment plans for induction therapy of newly-diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.21558.
Livingston, B., Bonner, A. & Pope, J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 20, 1345–1355 (2011).
Crow, Y. J. Lupus: How much “complexity” is really (just) genetic heterogeneity? Arthritis Rheum. 63, 3661–3664 (2011).
Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
Lau, K. K., Ault, B. H., Jones, D. P. & Butani, L. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J. Pediatr. Health Care 22, 282–288 (2008).
Hagelberg, S. et al. Long-term follow-up of childhood lupus nephritis. J. Rheumatol. 29, 2635–2642 (2002).
Pereira, T. et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin. J. Am. Soc. Nephrol. 6, 2192–2199 (2011).
Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937–941 (2010).
Zahr, N. et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 62, 2047–2054 (2010).
Díaz-Lagares, C. et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun. Rev. http://dx.doi.org/10.1016/j.autorev.2011.10.009.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Cimaz, R. Treating lupus nephritis in children—is there a gold standard?. Nat Rev Rheumatol 8, 192–193 (2012). https://doi.org/10.1038/nrrheum.2012.19
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.19
This article is cited by
-
The treatment of systemic lupus proliferative nephritis
Pediatric Nephrology (2013)